Best Growth Stocks To Research – July 15th

Circle Internet Group, BlackRock, Longevity Health, Blueprint Medicines, Blackstone, Prologis, and Novo Nordisk A/S are the seven Growth stocks to watch today, according to MarketBeat’s stock screener tool. Growth stocks are shares of companies whose revenues and earnings are expected to grow at an above-average rate compared with the broader market. These firms typically reinvest profits back into research, development or expansion rather than paying dividends, which drives higher valuation multiples. Investors in growth stocks aim for capital appreciation, accepting greater volatility and risk if growth targets aren’t met. These companies had the highest dollar trading volume of any Growth stocks within the last several days.

Circle Internet Group (CRCL)

Founded in 2013, Circle’s mission is to raise global economic prosperity through the frictionless exchange of value. We intend to connect the world more deeply by building a new global economic system on the foundation of the internet, and to facilitate the creation of a world where everyone, everywhere can share value as easily as we can today share information, content, and communications.

Shares of NYSE CRCL traded down $6.75 during mid-day trading on Tuesday, hitting $197.95. 6,915,600 shares of the stock were exchanged, compared to its average volume of 37,452,563. The firm has a market cap of $44.05 billion and a price-to-earnings ratio of -15,643.27. Circle Internet Group has a twelve month low of $64.00 and a twelve month high of $298.99.

BlackRock (BLK)

BlackRock, Inc. is a publicly owned investment manager. The firm primarily provides its services to institutional, intermediary, and individual investors including corporate, public, union, and industry pension plans, insurance companies, third-party mutual funds, endowments, public institutions, governments, foundations, charities, sovereign wealth funds, corporations, official institutions, and banks.

Shares of BlackRock stock traded down $61.55 during midday trading on Tuesday, reaching $1,049.91. The company had a trading volume of 1,236,710 shares, compared to its average volume of 696,017. The company has a current ratio of 4.34, a quick ratio of 4.34 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $162.66 billion, a price-to-earnings ratio of 25.57, a price-to-earnings-growth ratio of 2.22 and a beta of 1.41. The stock has a fifty day simple moving average of $1,000.47 and a 200 day simple moving average of $970.92. BlackRock has a 1-year low of $773.74 and a 1-year high of $1,133.55.

Longevity Health (XAGE)

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing.

Shares of Longevity Health stock traded up $2.61 during midday trading on Tuesday, reaching $5.26. The company had a trading volume of 96,612,972 shares, compared to its average volume of 1,142,724. Longevity Health has a 1-year low of $2.20 and a 1-year high of $48.60.

Blueprint Medicines (BPMC)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.

Shares of Blueprint Medicines stock traded up $0.01 during midday trading on Tuesday, reaching $129.37. The company had a trading volume of 2,711,349 shares, compared to its average volume of 1,411,770. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 1.01. The company has a market capitalization of $8.35 billion, a price-to-earnings ratio of -52.37 and a beta of 0.89. The stock has a fifty day simple moving average of $117.02 and a 200 day simple moving average of $101.90. Blueprint Medicines has a 1-year low of $73.04 and a 1-year high of $129.49.

Blackstone (BX)

Blackstone Inc. is an alternative asset management firm specializing in real estate, private equity, hedge fund solutions, credit, secondary funds of funds, public debt and equity and multi-asset class strategies. The firm typically invests in early-stage companies. It also provide capital markets services.

Shares of Blackstone stock traded down $3.74 during midday trading on Tuesday, reaching $159.62. The company had a trading volume of 1,599,389 shares, compared to its average volume of 3,875,639. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $116.47 billion, a price-to-earnings ratio of 48.05, a price-to-earnings-growth ratio of 1.47 and a beta of 1.65. The stock has a fifty day simple moving average of $144.23 and a 200 day simple moving average of $150.55. Blackstone has a 1-year low of $115.66 and a 1-year high of $200.96.

Prologis (PLD)

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. At March 31, 2024, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 1.2 billion square feet (115 million square meters) in 19 countries.

PLD stock traded down $0.56 during midday trading on Tuesday, reaching $108.79. The company’s stock had a trading volume of 2,299,779 shares, compared to its average volume of 4,175,578. Prologis has a 52 week low of $85.35 and a 52 week high of $132.57. The stock has a market cap of $100.95 billion, a PE ratio of 27.11, a price-to-earnings-growth ratio of 2.77 and a beta of 1.23. The company has a quick ratio of 0.41, a current ratio of 0.41 and a debt-to-equity ratio of 0.56. The business’s 50-day simple moving average is $107.29 and its 200-day simple moving average is $109.60.

Novo Nordisk A/S (NVO)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

NVO stock traded down $1.29 during midday trading on Tuesday, reaching $67.65. The company’s stock had a trading volume of 3,355,323 shares, compared to its average volume of 7,313,239. Novo Nordisk A/S has a 52 week low of $57.00 and a 52 week high of $143.49. The stock has a market cap of $302.05 billion, a PE ratio of 19.99, a price-to-earnings-growth ratio of 1.33 and a beta of 0.64. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70. The business’s 50-day simple moving average is $70.35 and its 200-day simple moving average is $74.78.